The FDA granted final approval for Barr Pharmaceuticals to market a generic version of Kos Pharmaceutical's cholesterol drug Niaspan. The approval follows a licensing agreement between the two companies to settle a patent dispute clearing the way for Barr to market its generic product while also paying royalties to Kos.

Related Summaries